FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

Roche said the late-stage trial did not provide reliable evidence that ​the drug's use in combination with Pfizer's Ibrance ...

A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...

By Sneha S K March 9 (Reuters) - Bristol Myers Squibb on Monday said its experimental drug for a rare form of blood cancer ...

The content creator, 26, was diagnosed with a rare bile duct cancer nearly three years ago ...

The alternative medicine industry is expanding rapidly, fueled in large part by the surge of health-related content on social ...

Cancer treatment in India costs 3x more than average ailments. These duty cuts on medicines help reduce out-of-pocket costs in public and private hospitals.

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

The cancer drug tazemetostat (Tazverik) is being voluntarily withdrawn in the U.S. and all other markets over concerns about secondary cancers, drugmaker Ipsen announced. The company also said it is ...

The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs ...

Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising drug candidate ...